RecruitMe Clinical Trial

ADVL1412, A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
A study for young adults with recurrent or refractory solid tumors using study drug nivolumab
Sponsor:CHOP
Enrolling:Male and Female Patients
Age Range:Between 1 and 30 years old
IRB Number:AAAP1101
U.S. Government ID:NCT02304458
Contact: Alice Lee, MD: 212-305-2478 / al2041@cumc.columbia.edu
Additional Study Information:

This study is for young adults with recurrent or refractory solid tumors. The purpose of the study is to determine whether study drug nivolumab is beneficial to individuals with solid tumors. Another goal is to find the highest safe dose of nivolumab that can be given without causing severe side effects as well as learn what kind of side effects nivolumab can cause.

Do You Qualify?
Have you or your child been diagnosed with a solid tumor?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Alice Lee, MD
Email: al2041@cumc.columbia.edu
Phone: 212-305-2478